[go: up one dir, main page]

UA111717C2 - Склад для перорального введення і ліпофільні солі метилналтрексону - Google Patents

Склад для перорального введення і ліпофільні солі метилналтрексону

Info

Publication number
UA111717C2
UA111717C2 UAA201211733A UAA201211733A UA111717C2 UA 111717 C2 UA111717 C2 UA 111717C2 UA A201211733 A UAA201211733 A UA A201211733A UA A201211733 A UAA201211733 A UA A201211733A UA 111717 C2 UA111717 C2 UA 111717C2
Authority
UA
Ukraine
Prior art keywords
methylnaltrexon
oral introduction
lipophilic salts
lipophilic
salts
Prior art date
Application number
UAA201211733A
Other languages
English (en)
Inventor
Саєд М. Шах
Крістофер Річард Діоріо
Ерік С. Ернсперджер
Сюй Мин
Шареффі Кадум А. Аль
Джонатан Марк Кохен
Original Assignee
Уайт Елелсі
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA111717(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уайт Елелсі filed Critical Уайт Елелсі
Publication of UA111717C2 publication Critical patent/UA111717C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Даний винахід стосується композицій, що містять метилналтрексон або його сіль, і його композицій і складів для перорального введення.
UAA201211733A 2010-03-11 2011-10-03 Склад для перорального введення і ліпофільні солі метилналтрексону UA111717C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11
PCT/US2011/027913 WO2011112816A1 (en) 2010-03-11 2011-03-10 Oral formulations and lipophilic salts of methylnaltrexone

Publications (1)

Publication Number Publication Date
UA111717C2 true UA111717C2 (uk) 2016-06-10

Family

ID=44148539

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201602306A UA123856C2 (uk) 2010-03-11 2011-03-10 Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
UAA201211733A UA111717C2 (uk) 2010-03-11 2011-10-03 Склад для перорального введення і ліпофільні солі метилналтрексону

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UAA201602306A UA123856C2 (uk) 2010-03-11 2011-03-10 Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення

Country Status (32)

Country Link
US (8) US8524276B2 (uk)
EP (2) EP2371357B1 (uk)
JP (4) JP6143409B2 (uk)
KR (2) KR101982482B1 (uk)
CN (2) CN102918039B (uk)
AR (1) AR080491A1 (uk)
AU (1) AU2011224275B2 (uk)
BR (1) BR112012022873B1 (uk)
CA (1) CA2789798C (uk)
CL (1) CL2012002192A1 (uk)
CO (1) CO6630134A2 (uk)
CR (1) CR20120476A (uk)
EA (1) EA029096B1 (uk)
EC (1) ECSP12012208A (uk)
ES (1) ES2623926T3 (uk)
GE (1) GEP201606550B (uk)
GT (1) GT201200247A (uk)
HU (1) HUE033133T2 (uk)
IL (1) IL221452A (uk)
MA (1) MA34146B1 (uk)
MX (2) MX368805B (uk)
MY (1) MY160727A (uk)
NZ (3) NZ601595A (uk)
PE (1) PE20130063A1 (uk)
PH (1) PH12012501622A1 (uk)
PL (2) PL2371357T3 (uk)
SG (3) SG183133A1 (uk)
TN (1) TN2012000392A1 (uk)
TW (2) TWI589293B (uk)
UA (2) UA123856C2 (uk)
WO (1) WO2011112816A1 (uk)
ZA (1) ZA201808498B (uk)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266806A1 (en) 2003-04-08 2004-12-30 Sanghvi Suketu P. Pharmaceutical formulation
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2865389A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
US9061076B2 (en) 2007-05-25 2015-06-23 North Carolina State University Viral nanoparticle cell-targeted delivery platform
EA029096B1 (ru) 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
WO2013096444A1 (en) * 2011-12-19 2013-06-27 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA2954370A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
EP3902528A1 (en) * 2018-12-19 2021-11-03 Friulchem SpA Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
MX2021013488A (es) * 2019-05-07 2021-12-10 Bausch Health Ireland Ltd Formulaciones liquidas de dosis oral de metilnaltrexona.
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
WO1994008599A1 (en) 1992-10-14 1994-04-28 The Regents Of The University Of Colorado Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
EP0880352B1 (de) 1997-02-14 1999-11-17 Gödecke Aktiengesellschaft Stabilisierung von naloxonhydrochlorid
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
ES2361148T3 (es) * 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
KR100974842B1 (ko) 2001-10-18 2010-08-11 넥타르 테라퓨틱스 아편양 길항제의 중합체 공액
US6943251B2 (en) * 2001-11-29 2005-09-13 Schering Corporation Preparation of salts of 4-[4-[(1R)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3S)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]
BR0308452A (pt) 2002-03-14 2006-06-06 Euro Celtique Sa composições farmacêuticas e métodos de preparação de composição farmacêutica
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
EP1638607A1 (en) 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
US20040266806A1 (en) 2003-04-08 2004-12-30 Sanghvi Suketu P. Pharmaceutical formulation
EP1651136B1 (en) * 2003-07-15 2017-03-08 Evonik Corporation Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
JP2007514758A (ja) 2003-12-19 2007-06-07 シェーリング　コーポレイション 医薬組成物
EP1701703B1 (en) * 2003-12-31 2011-03-09 Bend Research, Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers and stabilizing polymers
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
JP5238255B2 (ja) 2004-09-30 2013-07-17 ベクトン・ディキンソン・アンド・カンパニー ガラス製容器内の残留物を削減又は除去するための方法及びそれにしたがって製造されたガラス製容器
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) * 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US8091568B2 (en) * 2006-08-16 2012-01-10 Novartis Ag Temporal photo-bleaching of colored lens care solutions and use thereof
EP2073797A2 (en) * 2006-10-11 2009-07-01 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CA2865389A1 (en) * 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
HUE025662T2 (en) 2007-03-29 2016-04-28 Wyeth Llc Peripheral opioid receptor and antagonists and their uses
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
KR20110004425A (ko) * 2008-05-07 2011-01-13 넥타르 테라퓨틱스 말초적 작용 오피오이드 길항제의 경구 투여
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
EA029096B1 (ru) 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Also Published As

Publication number Publication date
ES2623926T3 (es) 2017-07-12
EA029096B1 (ru) 2018-02-28
EA201270741A1 (ru) 2013-02-28
JP2016029054A (ja) 2016-03-03
MA34146B1 (fr) 2013-04-03
MX368805B (es) 2019-10-17
KR20180118260A (ko) 2018-10-30
PL3178472T3 (pl) 2022-02-14
KR20130010900A (ko) 2013-01-29
KR101913102B1 (ko) 2018-10-31
CN102918039A (zh) 2013-02-06
SG10201606618PA (en) 2016-09-29
TW201622724A (zh) 2016-07-01
GT201200247A (es) 2013-09-11
PL2371357T3 (pl) 2017-09-29
IL221452A (en) 2017-07-31
HK1245673A1 (zh) 2018-08-31
EP2371357B1 (en) 2017-02-01
WO2011112816A1 (en) 2011-09-15
ECSP12012208A (es) 2015-03-31
NZ601595A (en) 2015-01-30
PH12012501622A1 (en) 2012-11-05
KR101982482B1 (ko) 2019-05-27
US8956651B2 (en) 2015-02-17
US10376505B2 (en) 2019-08-13
US20140249171A1 (en) 2014-09-04
GEP201606550B (en) 2016-10-10
BR112012022873B1 (pt) 2021-09-14
US20160206612A1 (en) 2016-07-21
CA2789798C (en) 2020-09-22
JP6143409B2 (ja) 2017-06-07
SG183133A1 (en) 2012-09-27
TWI589293B (zh) 2017-07-01
ZA201808498B (en) 2019-08-28
HUE033133T2 (en) 2017-11-28
MY160727A (en) 2017-03-15
SG10201501821RA (en) 2015-05-28
AU2011224275A1 (en) 2012-08-23
CR20120476A (es) 2012-11-30
CN102918039B (zh) 2017-06-09
TW201141479A (en) 2011-12-01
US8524276B2 (en) 2013-09-03
CO6630134A2 (es) 2013-03-01
JP6647368B2 (ja) 2020-02-14
US20190117646A1 (en) 2019-04-25
JP2011190259A (ja) 2011-09-29
US10307417B2 (en) 2019-06-04
CN107308125A (zh) 2017-11-03
JP2017206553A (ja) 2017-11-24
BR112012022873A2 (pt) 2016-08-30
US20200121673A1 (en) 2020-04-23
IL221452A0 (en) 2012-10-31
AR080491A1 (es) 2012-04-11
US9314461B2 (en) 2016-04-19
AU2011224275B2 (en) 2015-10-01
CA2789798A1 (en) 2011-09-15
US20190314365A1 (en) 2019-10-17
US20130330407A1 (en) 2013-12-12
US20190117645A1 (en) 2019-04-25
US20120070495A1 (en) 2012-03-22
MX349145B (es) 2017-07-14
TWI605814B (zh) 2017-11-21
TN2012000392A1 (en) 2014-01-30
US10507206B2 (en) 2019-12-17
CL2012002192A1 (es) 2012-09-28
JP2019034958A (ja) 2019-03-07
NZ702826A (en) 2016-08-26
PE20130063A1 (es) 2013-02-11
CN107308125B (zh) 2021-07-16
UA123856C2 (uk) 2021-06-16
EP3178472B1 (en) 2021-10-27
MX2012009125A (es) 2012-09-07
EP3178472A1 (en) 2017-06-14
JP6429955B2 (ja) 2018-11-28
EP2371357A1 (en) 2011-10-05
NZ703564A (en) 2016-08-26

Similar Documents

Publication Publication Date Title
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
JOP20180102A1 (ar) مركب صيدلاني
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
IN2014DN10670A (uk)
UA109010C2 (en) Morpholino pyrividines and their use in therapy
DK3045164T3 (da) Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser
MY173521A (en) Trpv4 antagonists
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
EA201390799A1 (ru) Триазолопиридины
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
EA201400444A1 (ru) Производные 2-оксопиперидинила
EA201001353A1 (ru) Гидробромид ивабрадина
MX367773B (es) Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
UA116994C2 (uk) Стабілізована аморфна форма агомелатину, спосіб її одержання і фармацевтичні композиції, які її містять
MX2013008559A (es) Derivados de leptina.
TR201009166A2 (tr) Sefdinir içeren farmasötik bileşim için üretim yöntemi
TR201010859A2 (tr) Sefdinir içeren tablet formları.
EA201492173A1 (ru) Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе
UA114396C2 (uk) Фармацевтична композиція з антиішемічною та антигіпертензивною дією